X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion

X4 Pharmaceuticals is reducing its workforce by 43 employees (30%) and closing its Vienna facility710.

The restructuring aims to focus on advancing mavorixafor for chronic neutropenia treatment while optimizing U.S. promotion of XOLREMDI for WHIM syndrome7.

XOLREMDI (mavorixafor) is the first FDA-approved therapy for WHIM syndrome, indicated for patients 12 years and older13.

The company expects to decrease annual spending by $30-35 million and extend its cash runway into the first half of 20267.

X4 Pharmaceuticals maintains its timeline for full enrollment in the global Phase 3 clinical trial for chronic neutropenia by mid-202510.

The restructuring includes discontinuing research efforts and pausing pre-clinical drug candidate programs10.

Mavorixafor is a selective CXCR4 receptor antagonist that blocks the binding of C-X-C chemokine ligand 12 to CXCR41.

The FDA granted Breakthrough Therapy Designation to mavorixafor in WHIM syndrome and evaluated the New Drug Application under Priority Review3.

Sources:

1. https://pubmed.ncbi.nlm.nih.gov/39004659/

3. https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-fda-approval-xolremditm-mavorixafor

7. https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-announces-strategic-restructuring-to-drive-value-6vo3cyf3fv4c.html

10. https://www.globenewswire.com/news-release/2025/02/06/3021959/0/en/X4-Pharmaceuticals-Announces-Strategic-Restructuring-to-Drive-Value-and-Maximize-Opportunity-for-Mavorixafor-in-Chronic-Neutropenia.html